Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial

RA Furie, EF Morand, IN Bruce, S Manzi… - The Lancet …, 2019 - thelancet.com
Background Type I interferons are involved in systemic lupus erythematosus (SLE)
pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I …
被引用次数：363 相关文章
[HTML] manchester.ac.uk

[HTML][HTML] Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial

RA Furie, EF Morand, IN Bruce… - The Lancet …, 2019 - research.manchester.ac.uk
Background Type I interferons are involved in systemic lupus erythematosus (SLE)
pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I …

Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial

RA Furie, EF Morand, IN Bruce… - The Lancet …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Type I interferons are involved in systemic lupus erythematosus (SLE)
pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I …

Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial

RA Furie, EF Morand, IN Bruce, S Manzi… - The Lancet …, 2019 - Elsevier
Background Type I interferons are involved in systemic lupus erythematosus (SLE)
pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I …

[引用][C] Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial

RA Furie, EF Morand, IN Bruce, S Manzi… - The Lancet …, 2019 - cir.nii.ac.jp
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a
randomised, controlled, phase 3 trial | CiNii Research CiNii 国立情報学研究所 学術情報 …

Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.

RA Furie, EF Morand, IN Bruce, S Manzi… - The Lancet …, 2019 - europepmc.org
Background Type I interferons are involved in systemic lupus erythematosus (SLE)
pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I …

Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial

RA Furie, EF Morand, IN Bruce, S Manzi… - The Lancet …, 2019 - thelancet.com
Background Type I interferons are involved in systemic lupus erythematosus (SLE)
pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I …

Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial

RA Furie, EF Morand, IN Bruce, S Manzi… - The Lancet …, 2019 - research.monash.edu
Background: Type I interferons are involved in systemic lupus erythematosus (SLE)
pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I …
[PDF] manchester.ac.uk

[PDF][PDF] Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial

RA Furie, EF Morand, IN Bruce, S Manzi, KC Kalunian… - pure.manchester.ac.uk
Background Type I interferons (IFN) are involved in systemic lupus erythematosus (SLE)
pathogenesis. In phase 2, anifrolumab, a human monoclonal antibody to type I IFN receptor …
[PDF] manchester.ac.uk

[PDF][PDF] Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial

RA Furie, EF Morand, IN Bruce, S Manzi, KC Kalunian… - research.manchester.ac.uk
Background Type I interferons (IFN) are involved in systemic lupus erythematosus (SLE)
pathogenesis. In phase 2, anifrolumab, a human monoclonal antibody to type I IFN receptor …